Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy of hematologic malignancy.

Helen E Heslop1, Freda K Stevenson, Jeffrey J Molldrem

  • 1Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX 77030-2303, USA.

Hematology. American Society of Hematology. Education Program
|November 25, 2003
PubMed
Summary

This review explores three immunotherapy strategies for hematologic malignancies: genetic vaccines, peptide vaccines targeting myeloid proteins, and adoptive T-cell therapy. Improvements focus on enhancing immunogenicity, T-cell receptor affinity, and cell persistence for better cancer treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A reassessment of anti-CAR T-cell expansion strategies.

Blood·2026
Same author

Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT.

Transplantation and cellular therapy·2026
Same author

Erratum: Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Introduction to a review series on hemophagocytic lymphohistiocytosis.

Blood·2026
Same author

The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.

Blood·2026
Same author

Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.

Blood advances·2026

Area of Science:

  • Immunology and Cancer Therapy
  • Molecular Biology and Bioinformatics

Background:

  • Advances in understanding cell interactions and informatics have identified new immunotherapy targets.
  • Immunotherapy shows success in some hematologic malignancies and viral tumors, but faces limitations in broader application.
  • This review focuses on improving three key immunotherapy strategies for hematologic cancers.

Purpose of the Study:

  • To provide an overview of current immunotherapy strategies for hematologic malignancies.
  • To discuss limitations and potential improvements for genetic, peptide, and adoptive T-cell immunotherapies.
  • To highlight recent clinical experiences and future directions in cancer immunotherapy.

Main Methods:

  • Review of clinical experiences with genetic vaccines (DNA and viral vectors) for lymphoma and myeloma.

Related Experiment Videos

  • Analysis of peptide vaccines targeting myeloid tissue-restricted proteins (e.g., Proteinase 3) for CML and AML.
  • Examination of adoptive immunotherapy using T cells for relapsed malignancies and viral tumors.

    • Main Results:

    • Genetic vaccines show promise in clinical trials, with ongoing efforts to enhance immunogenicity and response duration.
    • Peptide vaccines, particularly those targeting azurophil granule proteins, are effective for T-cell responses; enhancing T-cell receptor affinity is a key area for improvement.
    • Adoptive T-cell therapy benefits relapsed malignancies and EBV-associated tumors, but faces challenges with cell persistence and tumor evasion.

    Conclusions:

    • Optimizing immunotherapy requires a deeper understanding of antigen-presenting cell and effector cell interactions.
    • Strategies to improve effector T-cell manufacturing, in vivo lymphocyte homeostasis, and gene therapy approaches are crucial.
    • Enhancing the persistence and function of adoptively transferred T cells is key to expanding immunotherapy's success in hematologic malignancies.